Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk
Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
01 April 2024
|
| In: |
British journal of cancer
Year: 2024, Jahrgang: 130, Heft: 10, Pages: 1687-1696 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-024-02638-2 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41416-024-02638-2 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41416-024-02638-2 
|
| Verfasserangaben: | Yu Tian, Volker Arndt, Hermann Brenner, Michael Hoffmeister, Jenny Chang-Claude [und viele weitere] |
| Zusammenfassung: | Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. |
|---|---|
| Beschreibung: | Gesehen am 10.07.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-024-02638-2 |